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Objectives: Treatment of human brucellosis demands antibiotic targeting into the mononuclear-
phagocytic system. The aim of this work was to prepare and characterize particulate carriers containing
gentamicin and to study their interactions with phagocytic cells and bactericidal activity against intra-
cellular Brucella melitensis.
Methods:Differentpoly(lactide-co-glycolide) (PLGA)polymerswith freecarboxylicend-groupwereused to
formulate micro- and nanoparticles containing gentamicin, by a water-oil-water solvent-evaporation tech-
nique. PLGA 502H and 75:25H microparticles were selected because they showed the highest gentamicin
loadings as well as good physico-chemical properties and sustained release in vitro.
Results:Gentamicin-containingmicrospheresofbothpolymersweresuccessfullyphagocytosedby infec-
ted THP-1 human monocytes, and immunocytochemistry studies revealed that the antibiotic reached
Brucella-specific compartments. A dose of 30 mg of encapsulated gentamicin was able to reduce intracel-
lular Brucella infection by 2.2 log.
Conclusions:Altogether, these results suggest that 502Hand75:25Hmicrospheresaresuitablecarriers for
gentamicin targeting inside human macrophages and thus for brucellosis treatment.
Keywords: microparticles, brucellosis, phagocytosis, drug delivery system
Introduction
Brucellosis is a worldwide zoonosis that affects over half a mil-
lion individuals every year.1 Human disease is the accidental
expression of the much more widespread disease in animals.2
Humans may also be infected through exposure to the brucellae
in laboratories and, due to their ability to infect humans through
aerosol exposure, it is recognized as a biosecurity safety level-3
organism. However, treatment of human brucellosis is not yet
solved.
After its entrance in the host, the monocytic-macrophagic
system is the target for the pathogen,3 where it is able not
only to survive but also to replicate.4 The pathogen evades host
defences by inhibiting endosome fusion with lysosomes5,6 and
finally may reach the endoplasmic reticulum.7 In fact, these bac-
teria may have an extreme preference for the intracellular envir-
onment despite their ability to live outside host cells. Thus,
brucellae inside the macrophage are protected not only from
the immune system (antibodies, complement) but also from
in vitro active antibiotics that do not reach therapeutic concen-
trations into those intracellular compartments. As a result, relapse
rates of 5–16% are obtained with different protocols in clinical
practice.8,9
Particulate systems have been proposed for intracellular deliv-
ery of antimicrobial agents, therefore targeting the intracellular
sites of infection, thereby helping to increase the therapeutic
index of antimicrobials in intracellular niches. Gentamicin is an
aminoglycoside that is very active in vitro against clinical isolates
of Brucella and has already been trapped in particulate systems
for targeting infected monocytes, with promising results.10–12
The purpose of the present work was to study the interactions
between gentamicin-containing carriers [micro- and nanoparticles
of poly(lactide-co-glycolide) (PLGA)] and human macrophages.
Among the parameters that control particle uptake by macro-
phages, size,13–15 hydrophobicity13 and zeta potential15,16 are
among the most significant ones. Furthermore, once inside the
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phagocytes, intracellular elimination of the pathogen can be
improved not only by the action of released antibiotic from par-
ticulate carriers, but also by phagocyte activation triggered by
particle uptake. In the case of Brucella, reactive oxygen produc-
tion seems to play an important role in pathogen destruction,
while nitric oxide plays a minor role in anti-Brucella activity.17
Therefore, physico-chemical properties regarding particle uptake
and macrophage oxidative burst was studied. Finally, intracellular
location of particles and delivered gentamicin, and its therapeutic
efficacy in the intracellular elimination of Brucella melitensis in
human monocytes was also determined.
Materials and methods
Cell culture
Two different monocytic-macrophagic cell lines were used. J774
tumorigenic monocytic murine cell line was from the ATCC (ATCC
TIB 67) and THP-1 cell line, human myelomonocytic cells display-
ing macrophage-like activity, was kindly provided by Professor
D. Raoult from the Unite´ des Rickettsies, Universite´ de la Mediter-
rane´e, Marseille, France.
J774 monocytes were maintained in DMEM supplemented with 2
mM L-glutamine (Gibco, Invitrogen, Carlsbad, USA) and 10% (v/v)
heat-inactivated FCS (Biochrom KG, Berlin, Germany). When
adherent cells reached confluent growth (every 3–4 days) the
medium was withdrawn, and cells were detached in 5 mL of the
medium. After collecting by centrifugation (400 g, 4 min), 106 viable
cells, counted in a haemocytometer (Neubauer Chamber) by the
Trypan Blue (Sigma-Aldrich, St Louis, MO, USA) exclusion method,
were transferred to 20 mL of fresh medium.
For THP-1 cell culture, 2 mM L-glutamine, 10% FCS, 100 U/mL
of penicillin base and 100 mg/mL of streptomycin sulphate (Gibco,
Invitrogen, Carlsbad, USA) were added to RPMI. Every 4 days, cells
were collected by centrifugation (400 g, 4 min) and after their resus-
pension in 2 mL of the medium, 106 viable cells, counted by the
Trypan Blue method, were transferred to 20 mL of fresh RPMI. For
their differentiation into macrophages, THP-1 cells were incubated
for 48 h in complete medium with 10 ng/mL of phorbol 12-myristate
13-acetate (PMA).18
Bacterial strain and culture medium
B. melitensis 16M (ATCC 23456, biotype 1) smooth virulent strain
was used. For bacterial growth, trypticase soy broth (TSB) was
purchased from bioMe´rieux (Marcy l’E´toile, France) and American
Bacteriological Agar was obtained from Pronadisa (Madrid, Spain).
Preparation of micro- and nanoparticles
PLGA micro- and nanoparticles containing gentamicin (Sigma-
Aldrich) were prepared by a water-oil-water solvent-evaporation
technique.19 Briefly, the antibiotic was dissolved in a phosphate
buffer, pH 6.0, solution containing 200 mg of polymer in 0.5%
poly-vinylalcohol (PVA, molecular weight 15 000; from BDH Sup-
plies, UK) dissolved in dichloromethane for microspheres or in ethyl
acetate for nanoparticle preparations. These two solutions were
mixed by ultrasonication for 1 min (Branson sonifier 450, Branson
Ultrasonics corp., Danbury, USA) under cooling, to form a W1/O
emulsion. This inner emulsion was added to 2 mL of 1% PVA (W2)
and homogenized by ultrasonication. The resulting (W1/O)W2 emul-
sion was poured into 50 mL of 0.2% PVA and continuously stirred
for, at least, 3 h at room temperature to allow solvent evaporation and
microsphere formation. After preparation, particles were isolated by
centrifugation (7000 g, 5 min for microparticles and 12 000 g, 30 min
for nanoparticles), washed three times with ultra pure water and
freeze-dried.
The copolymers of PLGA of different molecular weights, with
free terminal carboxylic group, were used: 13.7 and 34 kDa PLGA
50:50 (Resomer RG 502H, named as 502H, and RG 503H, named
as 503H) were obtained from Boehringer-Ingelheim (Ingelheim,
Germany). Medisorb of 25 kDa (7525 DL 2.5 A) (named as
75:25H) was provided by Alkermes (Wilmington, USA).
Particle size and zeta potential
Size of microspheres was determined by laser diffractometry
(Mastersizer, Malvern Instruments, UK). A small amount was dis-
persed in water and analysed under continuous stirring. The average
particle size was expressed as the volume mean diameter in micro-
metres.
Size and polydispersity of nanospheres were analysed by Photon
Correlation Spectroscopy (PCS), using a Zetamaster analyser sys-
tem (Malvern Instruments, UK).
The zeta potential of all formulations, dispersed in ultra pure
water, was performed using the same apparatus.
Both particle sizing and zeta potential measurements were made
in triplicate for a single batch of particles and the results were the
average of three measurements.
Gentamicin loading
A known amount of accurately weighed loaded particles were dis-
solved in 1 mL of dichloromethane and the antibiotic was extracted
using 2 mL of phosphate buffer, pH 6.0. Drug was assayed in the
aqueous phase after its derivatization with o-phthalaldehyde (OPA)
using a fluorescence assay.20 Standard concentrations of gentamicin
were prepared by serial dilution in boric acid 0.4 M, pH 9.7, and
added to a 96-well microplate (TPP, Trasadingen, Switzerland).
Samples were also diluted, when needed, in boric acid. Then,
OPA solution [0.04% OPA, 0.1% (v/v) diethyl ether, 0.2% (v/v)
b-mercaptoethanol in boric acid] was added to the standard solutions.
Fluorescence was measured, immediately, in a Tecan GENios
fluorimeter (TecanGENios, Tecan Group Ltd, Maennedorf, Switzer-
land) (excitation: 340 nm, emission 450 nm) and sample concentra-
tions were calculated by means of the standard curve.
Oxidative burst of monocytes after particle uptake
Monocytes produce reactive oxygen metabolites together with other
non-oxygen dependent products, upon stimulation or during phago-
cytosis, which constitute an essential mechanism of host defence
against bacterial and fungal infections.21 Therefore determination
of oxidative burst (intracellular H2O2 production) can become a
suitable tool to measure monocyte activation after particle uptake.
Flow cytometry was used for oxidative burst quantification with a
FACSCalibur cytometer and the CellQuest computer program
(Becton Dickinson, San Jose, USA), after incubation with particles.
Oxidative burst was quantified by oxidation of dihydrorhodamine
123 to rhodamine 123, a green fluorescent product (Bursttest,
ORPEGEN Pharma, Heidelberg, Germany). Briefly, 20 mL of
1 mg/mL of particles in DMEM with L-glutamine (Gibco, Invitrogen,
Carlsbad, USA), previously opsonized with 10% fresh serum, was
incubated with 100 mL of 1.5–2.5 · 106 J774 cultured monocytes/mL
in test tubes (Falcon, BD, Franklin Lakes, NJ, USA) at 37C and 5%
CO2 for 4 h. Afterwards, the substrate was added and after vigorous
shaking tubes were incubated for 10 min. Cells were washed and the
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oxidative burst was measured from 10 000 cell events. Monocytes
were discriminated by forward scatter and 90 light scatter signals,
further selected by electronic gating in blood samples, and fluores-
cence (FL1-H) was measured using a logarithmic scale of 1024
channels. PMA incubated with the cells and cultured monocytes
or blood without previous contact with particulate material were
used as high burst and basal burst controls, respectively. Results
are expressed as FL1-H increases or decreases relative to controls.
Cytotoxicity of particles on THP-1 monocytes
Trypan Blue dye exclusion assay. Briefly, THP-1 cells were adjusted
to 2 · 106 monocytes/mL and 500 mL per well was added to 24-well
plates (Corning Corporation Inc., Acton, USA) and differentiated
into macrophages as described above. After removing non-adherent
cells they were incubated with 1 mg/mL particle dispersion in RPMI
complete medium for 24 h. Incubation medium was withdrawn and
cells were carefully detached with trypsin–EDTA (Gibco, Invitrogen,
Carlsbad, USA). An aliquot of the cell suspension was diluted 1:1
(v/v) with 0.4% Trypan Blue and viable and dead cells were counted
in a Neubauer chamber (Brand, GmbH & Co., Wertheim/Main,
Germany). Results were expressed as the percentage of cell viability
compared with particle-free medium.
MTT assay. Viable cells are able to reduce MTT (3-[4,5-
Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) (Sigma-
Aldrich, St Louis, USA) to coloured formazan serving as an indirect
measurement of cell viability.22,23 Cells were differentiated to mac-
rophages and incubated with particulate carriers as described for
Trypan Blue assay. Incubation medium was withdrawn, and cells
were washed twice. To each well, 500 mL of the MTT (methyl-
thiazol-tetrazolium) solution was added. Previously, MTT had
been dissolved at 5 mg/mL in RPMI complete medium, diluted
10 times and filtered. Cells were incubated with the MTT solution
for 1 h, supernatants discarded and formazan crystals dissolved in an
extraction solution [10% SDS in dimethyl formamide and water
(1:1, v/v), adjusted to pH 4.7 with acetic acid] overnight at 37C.
Formazan quantification was performed by measuring the absorbance
at 570 nm after sample dilution in extraction solution and thorough
mixing. After centrifugation, particle-free supernatants were
obtained. Previous measurements for different initial cell concentra-
tions and sample dilution showed that absorbance was proportional to
the number of viable cells. Results of cell viability were calculated as
the percentage of formazan: formation of this product by cells
co-incubated with particles, over the formation after incubation of
cells in a particle-free medium.
Intracellular location of Brucella, microparticles
and gentamicin
B. melitensis-infected macrophages which had phagocytosed PLGA
microspheres were processed for immunocytochemistry studies.
Brucella and gentamicin were labelled with immunogold beads as
described below and transmission electron microscopy images were
obtained.
Several colonies of B. melitensis 16M were incubated in TSB for
20 h, to let the bacteria reach exponential growth phase. Absorbance
was adjusted to 0.09 (600 nm), further diluted to an adequate bac-
terial suspension (100 bacteria/cell) and opsonized (30 min, 37C)
with a subagglutinant concentration of serum from a patient infected
with B. melitensis. Bacterial suspension was added to a well con-
taining 2 · 105 cells/mL of adherent THP-1 macrophages and, after
30 min incubation, five washes were performed to eliminate non-
phagocytosed bacteria. At 18 h post-infection, 30 mg/well of either
free or particle-loaded gentamicin, resuspended into 1% lecithin in
RPMI, was added to infected cells and incubated for further 24 h.
Cells were detached with trypsin–EDTA and fixed for 1 h at 4C in
2 mL of 4% glutaraldehyde (in 0.1 M sodium cacodylate buffer,
pH 7.3) After washing with sucrose-cacodylate buffer (0.25 M
sucrose in 0.1 M sodium cacodylate), cells were post-fixed with
2 mL of 1% osmium tetroxide (Johnson Matthey Chemicals,
London, UK) (in phosphate buffer, pH 7.3) for 1 h at 4C. One
wash was made with veronal buffer (56 mM sodium acetate, 28 mM
sodium barbital, 94 mM NaCl, 4 mM KCl, 0.9 mM CaCl2) and cells
were embedded in 200 mL of 2% melted agarose and kept at 4C
overnight to harden. Agarose was cut into 1 mm3 pieces and dehyd-
rated with an ethanol series and two immersions in propylene oxide
(15 min each) were performed. Samples were immersed 2 h in
prolilene:Epon (1:1) and embedded in pure Epon 812. Afterwards,
resin was polymerized by a gradual temperature increase (from 37 to
60C within 48 h).
Semi-thin sections of 1 mm were stained with Toluidine Blue
[absolute alcohol in deionized water (1:1), 1% Toluidine Blue,
50 mM Na2B4O7] to select suitable fields for electron microscopy.
Afterwards, by means of a Leica Ultracut R ultramicrotome (Leica,
Wetzlar, Germany) ultra-thin sections were prepared. For immuno-
cytochemistry, as primary antibodies, rabbit anti-gentamicin and
mouse anti-Brucella serum, both diluted 1:10, were incubated over-
night at 4C. After several washings, the secondary antibodies con-
jugated with different size of colloidal gold particles were used:
20 nm goat-anti rabbit and 10 nm for goat anti-mouse IgG (BBI
International, Sigma-Aldrich, St Louis, USA) both diluted 1:20 were
incubated for 60 min at room temperature. Samples were washed
again and further contrasted with uranyl acetate (4 min, room tem-
perature) and lead citrate (2 min, room temperature). For microscopy
studies a Zeiss EM10CR transmission electron microscope (TEM)
was used.
Brucella infection in human monocytes and treatment
with gentamicin-loaded particles
THP-1 macrophages were infected with B. melitensis and further
incubated with PLGA microspheres as described above. After
incubation of formulations for 24 h, several washes were performed
to remove non-phagocytosed particles or bacteria and extracellular
fractions were collected. Cells were detached with trypsin–EDTA
and after three freeze–thawing cycles macrophages were lysed. The
number of intracellular bacteria was calculated by subtracting the
number of extracellular bacteria from the total bacterial counts in
three wells.
Statistical analysis
For comparisons among more than two groups one-way analysis of
variance (ANOVA) was performed and as post-hoc tests Dunnett’s
test and Tukey B24 were used. When two groups were compared, the
Student’s t-test was performed. Statistical significance levels were
defined as follows: *P < 0.05; **P < 0.01.
Results
Characterization of particulate carriers
Different PLGA polymers with free carboxylic end-group were
used to formulate micro- and nanoparticles, differing in their
lactic:glycolic ratio and in their molecular weight.
Microspheres to treat Brucella-infected monocytes
551
 at Universidad de Navarra on Septem
ber 15, 2010
jac.oxfordjournals.org
D
ow
nloaded from
 
Microparticles
As shown in Table 1, gentamicin-containing microspheres
showed mean diameters in the range of 3.0–3.9 mm. Regarding
polymer type, all formulations showed a negative zeta potential,
between –17 and –24 mV. Loaded and unloaded microparticles
displayed different surface charges (P < 0.05), except for 503H
microparticles. This fact showed the different distribution of the
antibiotic among formulations. For 503H microspheres, gentami-
cin would be entrapped inside the microspheres, while for the
other formulations part of the drug would be also exposed to
particle surface.
No statistical differences were observed in drug loading
among microspheres. Those made of PLGA 503H presented
the highest loading (9.3 mg/mg), while 502H and 75:25H micro-
particles entrapped 8 mg/mg (Table 1).
Nanoparticles
Size distribution was narrow and monodispersed with an average
size of 300 nm (Table 1). No differences were observed between
loaded and empty formulations.
Similarly to microspheres, nanospheres showed negative zeta
potentials (–15 to –19 mV). Differences (P < 0.01) observed
between loaded and unloaded particles indicated the presence
of antibiotic on particle surface. Finally, compared with micro-
spheres, these formulations showed a lower gentamicin loading
(6.1 mg/mg) (P < 0.05).
Monocyte activation upon particle uptake:
determination of oxidative burst
Particle phagocytosis by monocytes promotes its activation and
production of reactive oxygen products25 among others. J774
murine macrophage activation upon particle uptake was evalu-
ated by measuring oxygen products (H2O2) by flow cytometry
(Figure 1). Results were expressed as the percentage of cells
emitting fluorescence (Figure 1a) and mean fluorescence
(Figure 1b). Nanospheres made of PLGA 502H were the most
activating particles, followed by microparticles made of the same
polymer. Microspheres of 75:25H polymer activated monocytes
to a lesser extent, but still differed significantly from basal oxid-
ative burst (P < 0.05), while 503H microspheres hardly promoted
H2O2 production.
Cytotoxicity of micro- and nanoparticles
Since clinical use is the final aim of these particulate carriers,
toxicity studies were performed in human monocytic cell line,
THP-1. Viable and dead cells can be differentiated by Trypan
Blue exclusion assay, since the dye can only enter dead cells.
After 24 h incubation of macrophages with particles, cell viability
was not compromised. Microspheres showed cell viabilities
above 97%, and nanoparticles above 90% (data not shown).
Absence of cytotoxicity was also observed by MTT assay.
This technique correlates formazan production with cell viability,
since a lower formation of this compound compared with parti-
cle-free media would be indicative of cell toxicity. For all for-
mulations, formazan levels were always lower than negative
control, indicating absence of toxicity. Even higher amounts
(P < 0.01) were detected for cells incubated with 502H micro-
spheres. They produced more than twice as much formazan as
basal cells. This overproduction may be related to an activation of
the metabolic status of the cells22 by enhanced activity of mito-
chondrial dehydrogenase enzyme26 (Figure 2).
Therefore, 502H and 75:25H microspheres, which showed the
highest gentamicin loadings and were able to activate monocytes,
were selected to perform further studies.
Intracellular location of Brucella,
microparticles and gentamicin
In an attempt to determine whether microspheres and/or genta-
micin reach pathogen’s compartment, gold-labelled transmission
electronic microscopy studies were carried out. In these studies
microspheres of 502H and 75:25H polymers were selected for
additional studies due to their lower cytotoxicity and higher drug
loading compared with nanospheres of PLGA 502H as well as
their ability for oxidative burst triggering.
Microparticles of both polymers were successfully phagocyt-
osed and no degradation was observed 24 h post-incubation
Table 1. Characteristics of gentamicin (GEN)-containing microparticles (MP) and nanoparticles (NP)
Polymer and particle type Size (nm) Zeta potential (mV)
GEN loading
(mg GEN/mg particle)b
502H NP GEN-loaded 310 – 2.0 (0.22)a –15.5 – 0.2 6.1 – 0.4**d
unloaded 300 – 2.1 (0.15)a –19.4 – 1.1**c –
502H MP GEN-loaded 3.9 – 0.2 –21.5 – 0.5 8.2 – 0.4
unloaded 2.2 – 0.9 –24.3 – 0.7*c –
503H MP GEN-loaded 3.4 – 0.2 –18.2 – 1.5 9.3 – 0.6
unloaded 2.9 – 0.2 –19.1 – 0.9 –
75:25H MP GEN-loaded 3.0 – 0.2 –17.1 – 0.4 8.1 – 0.4
unloaded 1.4 – 0.1 –20.2 – 1.2*c –
Data are expressed as means – SD of three measurements.
aPolydispersion of nanoparticles size.
bNominal loading: 10 mg gentamicin.
cStudent’s t-test was performed between zeta potentials of loaded and unloaded particles: *P < 0.05; **P < 0.01.
dTukey B test was used for comparison among formulations: *P < 0.05; **P < 0.01.
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(Figure 3). However, after its release from microspheres, genta-
micin was observed in cell cytoplasm and even in the nucleus
(Figure 4). There was no evidence of fusion of endosomes
harbouring Brucella and microspheres, but gentamicin was detec-
ted inside the pathogen’s vesicles. It seemed that microspheres
were degraded and the released antibiotic was distributed to cell
cytoplasm and from there was able to enter Brucella’s niche
(Figure 4).
Therapeutic efficacy of gentamicin-containing
microspheres in intracellular elimination of
B. melitensis in human monocytes
Intracellular Brucella reduction after co-incubation with PLGA
gentamicin-loaded microspheres in THP-1 human monocytes was
studied and compared with free antibiotic. A dose of 30 mg of
gentamicin per well, either free or particle-loaded, was added to
the cell culture. The same amount of empty particles was used as
a control. Free gentamicin was able to eliminate 0.96 log of the
intracellular bacteria, which meant that despite its hydrophilic
nature it was able to enter monocytes under our experimental
conditions, confirming previous results described above. Reduc-
tion of infection was higher (P < 0.01) when gentamicin was
encapsulated into PLGA microspheres, being similar for both
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Figure 1. Oxidative burst of J774 macrophages after particle uptake. Results are expressed as (a) the percentage of activated cells (apercentage of cells producing
oxygen reactives) and (b)mean fluorescence. Bars representmeans – SD ofmeasurements performed on three different days. *P < 0.05, Dunnett test, comparedwith
negative control.
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Figure 2. MTT assay: formazan production after incubation of THP-1 macro-
phages with PLGA formulations. Cells (106 cells/well) were incubated with
1mg/mL of particle suspension for 24 h before the assaywas performed. Results
were calculated as the percentage of formazan production by cells co-incubated
with particles with respect to incubation in particle-free medium. Results are
expressed as means – SD of three measurements. **P < 0.01, Dunnett test,
compared with negative control.
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Figure 3. Immunogold labelling of THP-1 macrophages. Cells were infected
with Brucella melitensis (BM) and further incubated with PLGAmicroparticles
(MP): 75:25H (a) or 502H (b). Many phagocytosed microspheres (MP) can be
observed but did not reach pathogen’s intracellular compartment.
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polymers: 2.17 logs for 75:25H microparticles and 2.18 for 502H
microparticles. Unloaded particles did not show any bactericidal
effect (Table 2).
Discussion
Gentamicin is an antibiotic that is rapidly bactericidal against Bru-
cella in vitro; however, it crosses cell membranes poorly, and there-
fore its role in the treatment of human brucellosis is limited, and it
must be used in combinationwith other antimicrobials.27 Even then,
treatment failures and relapses of human brucellosis remain a prob-
lem.8 After its entry into the host, Brucella resides mainly in pha-
gocytic cells, being able to survive and even replicate inside
them.4,28 The access of any antibiotic to Brucella’s niche is essen-
tial and ‘drug delivery systems’ may help to achieve this goal.
Therefore, intracellular antibiotic efficiency of gentamicin-loaded
microspheres in the context of B. melitensis-infected humanmono-
cytes was examined in vitro with a view to developing improved
therapies for the treatment of brucellosis. We had previously repor-
ted that treatment with gentamicin microencapsulated into PLGA
50:50Hmicrospheres decreased the number of intracellular bacteria
significantly.29 However, murine monocytes were used for infec-
tion studies with Brucella abortus. Now, we have considered the
use of the more virulent B. melitensis species to in vitro infect
human macrophages, in order to mimic the natural conditions dur-
ing human brucellosis. On the other hand, themethod of preparation
previously used was based on the spray-drying technique that ren-
dered a high degree of aggregation among particles.30 Therefore, in
the current report, solvent-evaporation method was the technique
which successfully encapsulated gentamicin in PLGA nano- and
microparticles.31
Microspheres obtained here, in the range of 2–4 mm, are
expected to be successfully taken up by the monocytic-macro-
phagic system,15,30 as well as nanoparticles that despite their
smaller size should also be cleared by the phagocytic cells.32
Actually, in vitro activation of human monocytes indicated
that particles of end-group uncapped polymers triggered reactive
oxygen production, with the exception of microspheres made by
PLGA 503H, PLGA 502H being the most activating polymer.
Nanoparticles made of this polymer promoted the highest burst,
which could be related to its higher contact surface with the
monocyte. Moreover, in agreement with Prior et al.24 who
described that less negatively charged particles were phagocyt-
osed more efficiently, gentamicin-loaded nanospheres with a
lower charge than microspheres of 502H polymer led to a higher
cell activation upon uptake (Table 1).
Molecular weight of PLGA polymers seems to influence react-
ive oxygen formation, since particles with higher molecular
weight (503H microspheres; molecular weight 34 kDa) exerted
no oxidative burst and 75:25 H (24 kDa) resulted in less activa-
tion than 502H (13.7 kDa).
Macrophage viability was not compromised after incubation
with the PLGA formulations. Our results agree with literature
data about lack of toxicity of these copolymers.19,33,34 A slight
10% loss of viability observed with the nanoparticles could be
due to extremely high oxidative burst triggered by these particles
which would have released a high quantity of toxic free radicals
from these cells. In addition, an increased activation status after
502H microsphere uptake was observed by MTT assay. This
enhanced metabolic status was related to mitochondrial dehyd-
rogenase activity, and our results suggested that it was independ-
ent of oxidative burst, since nanoparticles were unable to promote
high formazan production but activated oxidative burst to a high
extent.
Oxidative burst upon phagocytosis is known to play an import-
ant role in intracellular Brucella elimination since reactive oxy-
gen production enhancers increased anti-Brucella activity of
these cells, while inhibitors of these intermediates reduced
their bactericidal activity.17 Thus, optimal formulations should
be able to trigger reactive oxygen production of macrophages.
MP
BM
Figure 4. Detailed immunogold labelling of THP-1 macrophages infected with
Brucella melitensis (BM) and treated with gentamicin-containing PLGAmicro-
particles (MP). Gentamicin was detected (immunogold dots) not only inside
microspheres, in cell cytoplasm and in nucleus, but also inside Brucella’s com-
partment (short arrowheads).
Table 2. Efficacy of gentamicin (GEN)a free or loaded in PLGA
microparticles against intracellular Brucella melitensis infection in
THP-1 human macrophages
Treatment
Intracellular
cfu (log) – SDb
Reduction
(log)c
Statistical
significanced
e f
Negative control 6.46 – 0.03 0.00
Free GEN 5.50 – 0.02 0.96 **
GEN-loaded 502H MP 4.28 – 0.30 2.18 ** **
GEN-loaded 75:25H MP 4.29 – 0.11 2.17 ** **
Unloaded 502H MP 6.45 – 0.07 0.01
Unloaded 75:25H MP 6.46 – 0.06 0.00
aGentamicin concentration: 60 mg/mL.
bData are the average – SD of three measurements.
cBacterial count reductions were performed compared with negative control.
dTukey B test was performed for statistical analysis.
eComparisons were performed between all treatments and control without treat-
ment: *P < 0.05; **P < 0.01.
fComparison between free and loaded microparticles with free gentamicin:
*P < 0.05; **P < 0.01.
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Therefore, based on these observations, 502H and 75:25H micro-
spheres, which showed the highest gentamicin loadings and were
able to activate monocytes, were selected to perform further
electron microscopy and immunocytochemistry studies.
By transmission electron microscopy lack of fusion was
observed between both microspheres and the pathogen’s niche.
However, the antibiotic released from the particles was observed
in the cytoplasm and nucleus and also entered the vacuoles
harbouring Brucella. Once inside lysosomes, upon particle
degradation,13 the antibiotic would be released to cytoplasm.35
Aminoglycosides are known to be lysosomotropic, because of
their protonation state at acidic pH, but different amino acid
transporters have been described in lysosomal membranes36,37
which could help antibiotic translocation to the cytoplasm and
subsequently enter the pathogen’s compartment. These findings
agree with Sandoval et al.,38–40 who proposed that the antibiotic
would follow a retrograde traffic from Golgi to endoplasmic
reticulum and after its release in cytoplasm it would bind to
mitochondria and nucleus.
Finally, the in vitro experimental infection demonstrated that
the released gentamicin from particles was active, being able to
exert its bactericidal effect inside the macrophagic cells. No
differences were found between both 502H and 75:25H micro-
sphere formulations.
In conclusion, gentamicin-loaded microspheres were effective
in killing intracellular bacteria by way of efficiently targeting
microencapsulated antibiotic into B. melitensis’s niche and by
activation of oxidative burst in the macrophagic cells. These
results support further studies in animal models with 502H
and 75:25H microspheres carrying gentamicin for brucellosis
treatment.
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